Patents Examined by Erich A. Leeser
  • Patent number: 12030877
    Abstract: Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: July 9, 2024
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Kai Ding, Ziyuan Zhou
  • Patent number: 12023327
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12023326
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12023325
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12018034
    Abstract: Semisynthetic methods of preparing neosaxitoxin from cultures of the dinoflagellates Alexandrium pacificum and Gymnodinium catenatum are described. The scalable method includes the reductive desulfonation of an unresolved mixture of gonyautoxin 1 (GTX1) and gonyautoxin 4 (GTX4) using dithiol in a buffered reaction solvent at a pH of about 7.5.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: June 25, 2024
    Inventors: Andrew Ian Selwood, Roelof Van Ginkel, Craig Alan Waugh
  • Patent number: 12018029
    Abstract: The disclosure relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein X1 and X5 is each selected from CR1 or N; X2, X3 and X4 is each selected from CR1, CR2 or N, provided at least one of X2, X3 and X4 is CR2 and provided only one of X1, X2, X3, X4 and X5 can be N. R1, R2, R3, R4, R5, L1, L2 and L3 are as defined herein. Compounds according to Formula (I) are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: June 25, 2024
    Assignee: The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Leo Leung, Kiri North, Deborah Smithen, Mohammed Aljarah, Michael Brown, Ben Ayers, Dan Niculescu-Duvaz, Caroline Springer
  • Patent number: 12018028
    Abstract: Novel 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: June 25, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 12011446
    Abstract: A method of reducing the severity of radiation induced fibrosis (RIF) by administering to a patient at least a first dose of an MeK inhibitor such as trametinib between 0.01 mg to 2.0 mg, and after said radiation procedure, administering to said patient a further dose of the MeK inhibitor between 0.01 mg and 2.0 mg after the radiation procedure.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 18, 2024
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: Joel Rosenbloom, Edward John Macarak
  • Patent number: 12012393
    Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: June 18, 2024
    Assignee: Inthera Bioscience AG
    Inventors: Marc Labelle, Ulrich Kessler, Valentino Cattori, Cyril Cook, Ramkrishna Reddy Vakiti, Kevin R. D. Johnson, Matinder Kaur, Jean-d'amour K. Twibanire, Farman Ullah
  • Patent number: 12005067
    Abstract: The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Zheng Zhang, Melissa Parker, James Fidge
  • Patent number: 11993613
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 28, 2024
    Assignee: AbbVie Inc.
    Inventors: Puneet Kumar, Anthony Mastracchio, Mark Mills, Andrew William Phillips
  • Patent number: 11981677
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 14, 2024
    Assignee: Grünenthal GmbH
    Inventors: Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
  • Patent number: 11976068
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: May 7, 2024
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • Patent number: 11969414
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 30, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 11964980
    Abstract: Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: April 23, 2024
    Assignee: Blueprint Medicines Corporation
    Inventors: Joshua D. Waetzig, Gordon Wilkie
  • Patent number: 11945821
    Abstract: Novel 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: April 2, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Michelyne Haroun, Christophe Tratrat
  • Patent number: 11932619
    Abstract: A 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine compound, its synthesis, and its use as an anticancer agent.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
  • Patent number: 11931361
    Abstract: Described herein is a novel method for generation of recombinant poxviruses using an E3 and K3 double deletion mutant virus as the parental virus for generation of recombinant viruses. Following allowing for crossing over between the parental virus and an insertion cassette including an orthopox K3 peptide and the gene of interest, recombinant viruses are selected by infecting a host cell line permissive for the orthopox K3 peptide but not for the E3 and K3 double mutant parental virus. It is also demonstrated that a specific small molecule inhibitor of NEDD8 activating enzyme, MLN4924, can completely block poxvirus K3 family protein mediated PKR degradation and virus replication.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 19, 2024
    Assignee: Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health
    Inventor: Jingxin Cao
  • Patent number: 11931356
    Abstract: The invention provides compositions, compounds, formulations, and methods for treating HPV infections including pre-malignant infections and cancer. Compounds that covalently bind to the HPV E6 protein are disclosed.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: March 19, 2024
    Assignees: The Trustees of Indiana University, Kovina Therapeutics, Inc.
    Inventors: Elliot J. Androphy, Samy O. Meroueh, Zhijian Lu
  • Patent number: 11925639
    Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 12, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki